Diabetic Retinopathy

Diabetic retinopathy is the leading cause of blindness in working-age adults in the United States — and yet it is one of the most preventable causes of vision loss we know of. The single most important fact on this page is simple: in its early stages, diabetic retinopathy causes no symptoms at all. Your vision feels perfectly normal while damage is quietly accumulating in the back of your eye. By the time you notice blurring or floaters, the disease is often advanced. That is why a yearly dilated eye exam — painless, covered by most insurance, and over in about 30 minutes — is the cornerstone of keeping your sight. The exam catches the disease early, when treatment works best and vision can almost always be saved.

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
Research Papers
Connections
Featured Videos

1. Overview

Diabetic retinopathy is damage to the tiny blood vessels of the retina — the light-sensing tissue lining the back of the eye that works like the film in a camera. Chronic high blood sugar weakens and injures these vessels over years, causing them to leak, swell, close off, and eventually grow abnormal new vessels that bleed. It is a microvascular complication of diabetes, in the same family as the kidney damage (nephropathy) and nerve damage (neuropathy) that diabetes can cause elsewhere in the body. The retina just happens to be a place where doctors can see small-vessel disease directly, which is why the eye is often where diabetes first reveals its hidden toll.

The disease moves through stages. Non-proliferative diabetic retinopathy (NPDR) is the earlier, milder form, where vessels balloon into microaneurysms and leak fluid and blood. Proliferative diabetic retinopathy (PDR) is the advanced, sight-threatening form, in which the oxygen-starved retina grows fragile new blood vessels (neovascularization) that can bleed into the eye or pull the retina loose. Separately and at any stage, fluid can collect in the macula — the central part of the retina responsible for sharp, straight-ahead vision — producing diabetic macular edema (DME), the most common reason people with diabetes lose vision.

The encouraging reality is that vision loss from diabetic retinopathy is largely avoidable. Decades of clinical trials have shown that controlling blood sugar, blood pressure, and cholesterol slows the disease dramatically, and that modern treatments — injections that calm leaking vessels and lasers that quiet abnormal ones — can preserve or even restore sight when started in time. The system only fails when the disease is found too late, which is almost always a story of missed eye exams rather than treatments that did not work.

2. Epidemiology

Diabetic retinopathy is common, and it tracks closely with how long a person has had diabetes. Among adults with diabetes worldwide, a large pooled analysis found that roughly 35% have some degree of retinopathy and about 7% have vision-threatening retinopathy (proliferative disease or macular edema). In the United States, more than 9 million adults have diabetic retinopathy, and the number is rising as the prevalence of type 2 diabetes climbs.

Duration of diabetes is the strongest driver. Among people with type 1 diabetes, retinopathy is rare in the first few years but eventually affects the great majority — after 20 years, nearly everyone with type 1 has some retinopathy. In type 2 diabetes, because the disease often goes undiagnosed for years, roughly 1 in 5 people already have retinopathy at the time of diagnosis. This is exactly why screening schedules differ between the two types (see Prevention).

It is the human and economic stakes that make these numbers matter. Diabetic retinopathy is the leading cause of new cases of blindness among working-age adults (20–74 years) in the United States and much of the developed world. Because it strikes during peak earning and family years, its impact on livelihoods, independence, and quality of life is outsized — and almost entirely preventable with timely care.

3. Pathophysiology

To understand the disease, picture the retina as a dense, delicate net of microscopic blood vessels feeding hungry nerve cells. Chronically high blood glucose is toxic to the lining of these vessels in several overlapping ways. Excess sugar fuels harmful biochemical pathways (the polyol and hexosamine pathways, protein kinase C activation, and the buildup of advanced glycation end-products) and floods the tissue with oxidative stress. The net effect is slow, cumulative injury to the vessel wall.

One of the earliest casualties is the pericyte — a support cell that wraps around retinal capillaries and keeps them toned and sealed. As pericytes die off, capillary walls weaken and bulge outward into microaneurysms, the first sign visible on an eye exam. The weakened vessels become leaky, allowing fluid, proteins, and blood to seep into the retina, producing the dot-and-blot hemorrhages, hard exudates (lipid deposits), and swelling that define non-proliferative disease.

Over time, capillaries also close off entirely, leaving patches of retina starved of oxygen (ischemia). The oxygen-deprived retina sends out a chemical distress signal — chiefly vascular endothelial growth factor (VEGF) — that begs for new blood supply. VEGF does two damaging things. First, it makes existing vessels even leakier, driving macular edema. Second, in advanced disease it triggers neovascularization: the growth of fragile, disorganized new vessels on the retina and optic disc. These new vessels are the problem, not the solution — they bleed easily, causing vitreous hemorrhage, and grow along scaffolds of scar tissue that can contract and tear the retina away. VEGF's central role is precisely why anti-VEGF injections have become a cornerstone of treatment.

4. Etiology and Risk Factors

The root cause is chronic high blood sugar over a long period of time. Everything else either reflects that exposure or amplifies the damage. The good news is that the most powerful risk factors are modifiable — they are things you and your care team can change.

Duration of diabetes — the single biggest non-modifiable factor. The longer you have lived with diabetes, the higher the risk, which is why screening never stops.
Poor blood sugar control — a higher A1c (average blood sugar over ~3 months) strongly predicts retinopathy onset and progression. This is the most important factor you can change.
High blood pressure — hypertension stresses the same fragile retinal vessels and independently worsens retinopathy.
High blood lipids — elevated cholesterol and triglycerides are linked to the hard exudates and macular edema that threaten central vision.
Pregnancy — retinopathy can appear or progress quickly during pregnancy in women with pre-existing diabetes, so a dilated exam early in pregnancy is recommended.
Diabetic kidney disease — nephropathy and retinopathy travel together; the presence of one raises suspicion for the other.
Smoking — damages blood vessels throughout the body and adds insult to already injured retinal vessels.
Anemia and obstructive sleep apnea — both reduce oxygen delivery to the retina and are associated with more severe disease.

5. Clinical Presentation

The defining feature of early diabetic retinopathy — and the reason it is so dangerous — is that there are no symptoms. Early NPDR and even significant macular changes can be present while your vision feels completely normal. You cannot feel the disease, and you cannot tell from how well you see whether your retina is healthy. This is the central message of this entire article: normal vision is not proof of a healthy retina.

When symptoms finally do appear, they signal that the disease has progressed. Watch for:

Blurred or fluctuating vision — especially central blurring, often from macular edema; vision that varies day to day can track with blood-sugar swings.
Floaters — new spots, cobwebs, or specks drifting across your view, which can mean bleeding from abnormal vessels.
Dark or empty areas in your field of vision.
Difficulty seeing colors or trouble with night vision.
Sudden, severe vision loss — often a "curtain" or a shower of dark floaters from a vitreous hemorrhage (bleeding into the gel of the eye) or a retinal detachment. This is an emergency — seek eye care urgently.

Because symptoms arrive late, the goal is never to wait for them. The whole point of screening is to find and treat the disease in the silent phase, long before a single floater appears.

6. Diagnosis

Diagnosis rests on looking directly at the retina, which only an eye care professional can do properly. The core tools are:

Dilated eye exam — the foundation. Drops widen the pupil so the doctor can examine the entire retina with a bright light and lens, spotting microaneurysms, hemorrhages, exudates, and new vessels. Painless, takes about 30 minutes including dilation, and is the test that catches silent disease.
Optical coherence tomography (OCT) — a quick, non-invasive scan that takes a cross-section "ultrasound with light" of the retina. It is the gold standard for detecting and measuring macular edema, showing exactly where fluid is collecting and by how much, and for tracking response to treatment.
Fluorescein angiography — a dye injected into an arm vein travels to the retina, and a camera photographs how it flows. It pinpoints leaking vessels, areas of capillary closure (ischemia), and neovascularization, guiding laser and injection treatment.
Fundus photography — high-resolution color photos of the retina that document the disease and allow precise comparison over time, including wide-field cameras that capture far more of the retina in a single image.
AI-based screening — an emerging tool. Computer algorithms can now read retinal photos and flag people who need referral, making screening possible in primary-care offices and pharmacies. The first such system was FDA-authorized in 2018, and these tools are expanding access where eye specialists are scarce.

Findings are graded by severity — from mild, moderate, and severe NPDR up to PDR — and the presence or absence of macular edema is noted separately. This staging drives how often you are seen and whether treatment is needed now or watchful monitoring is enough.

7. Treatment

Treatment has two layers: a foundation that applies to everyone with diabetes, and eye-specific procedures for sight-threatening disease.

The foundation — controlling sugar, pressure, and lipids. This is not a footnote; it is the most powerful intervention in the entire disease. The landmark Diabetes Control and Complications Trial (DCCT) in type 1 diabetes and the United Kingdom Prospective Diabetes Study (UKPDS) in type 2 diabetes proved that tight blood-sugar control sharply reduces the onset and progression of retinopathy — and that the benefit persists for years afterward (the "legacy effect" or metabolic memory). Controlling blood pressure adds further protection. Good metabolic control can prevent retinopathy from ever becoming serious, and slows it even after it appears.

Anti-VEGF injections. Because VEGF drives both macular edema and abnormal vessel growth, medicines that block it — aflibercept (Eylea), ranibizumab (Lucentis), and bevacizumab (Avastin) — are now first-line for diabetic macular edema and increasingly used for proliferative disease. They are given as a quick injection into the eye (numbed first), usually monthly at the start and then spaced out. The head-to-head DRCR.net Protocol T trial compared all three and found they all improved vision, with aflibercept offering an edge when starting vision was poorer. The Protocol S trial showed ranibizumab can match laser for proliferative disease while better preserving peripheral and night vision.

Laser photocoagulation. Lasers remain valuable and reliable. Focal/grid laser seals individual leaking spots in macular edema (now often combined with or replaced by injections). Panretinal photocoagulation (PRP) treats proliferative disease by placing hundreds of small burns across the peripheral retina; this deliberately reduces the oxygen-starved tissue that is screaming for VEGF, causing the dangerous new vessels to shrink and bleeding to stop. PRP is a proven, durable, one-or-two-session treatment that has prevented countless cases of blindness.

Vitrectomy. When bleeding fills the eye and does not clear, or when scar tissue is pulling on the retina, a surgeon performs a vitrectomy — removing the blood-clouded gel and scar tissue, repairing detachment, and often applying laser at the same time. It is the rescue operation for the most advanced disease and can recover useful vision that would otherwise be lost.

8. Complications

Left untreated, advanced diabetic retinopathy can damage vision through several mechanisms:

Diabetic macular edema (DME) — the most common cause of vision loss in diabetes; fluid swelling the central retina blurs the sharp vision you use for reading, driving, and faces.
Vitreous hemorrhage — fragile new vessels bleed into the clear gel of the eye, causing sudden floaters or a dramatic loss of vision.
Tractional retinal detachment — scar tissue contracts and physically pulls the retina off the back wall of the eye, which can cause permanent blindness if not repaired.
Neovascular glaucoma — abnormal vessels grow over the eye's drainage angle, blocking fluid outflow and driving eye pressure dangerously high; this can be painful and sight-destroying.
Permanent vision loss or blindness — the end result when the above complications go untreated.

The recurring theme is that each of these is far easier to prevent than to reverse, and each is usually preceded by months or years of silent, treatable disease.

9. Prognosis

Here is the honest, two-sided truth. When diabetic retinopathy is caught early and managed well, the outlook is excellent — most people keep good vision for life. The treatments we have are genuinely effective: anti-VEGF injections, laser, and surgery, combined with good blood-sugar control, prevent the vast majority of severe vision loss. The classic studies estimate that timely treatment plus appropriate follow-up can reduce the risk of severe vision loss by over 90%.

The flip side is equally honest. When the disease is found late — after vitreous hemorrhage, after the macula has been swollen for a long time, after a detachment — treatment can stabilize and often improve vision, but it may not fully restore what was lost. Some damage becomes permanent. This is why prognosis is so tightly linked to screening: the outcome is determined less by how aggressive the disease is and more by how early it is found.

Prognosis also requires ongoing care. Diabetic retinopathy is a chronic condition that needs continued monitoring even after successful treatment, because new leakage and new vessel growth can recur. The realistic, empowering message is that with regular eye exams and good control of sugar, blood pressure, and lipids, the great majority of people with diabetes will never go blind from this disease.

10. Prevention

This is where you have the most power. Diabetic retinopathy is one of the few major causes of blindness that is genuinely preventable, and prevention comes down to a short, concrete checklist.

Master the controllable trifecta. Three numbers do most of the work:

A1c — keep your average blood sugar in your individualized target range (often around 7% for many adults, but personalized with your doctor). This is the strongest lever you have.
Blood pressure — control hypertension; it independently protects the retina.
Lipids — manage cholesterol and triglycerides, which are tied to macular edema.

Do not smoke. Smoking injures blood vessels everywhere, including the retina. Quitting is one of the best things you can do for your eyes and the rest of your body.

Get on the eye-exam schedule and stay on it. This is the safety net that catches the disease in its silent phase:

Type 2 diabetes: have a dilated eye exam at the time of diagnosis, because retinopathy may already be present, then at least once a year after.
Type 1 diabetes: begin annual dilated exams within 5 years of diagnosis (retinopathy is uncommon before then), then at least yearly.
Pregnancy with pre-existing diabetes: have an exam early in pregnancy and follow your eye doctor's schedule, since the disease can progress quickly.
Your eye doctor may recommend more frequent exams if you already have retinopathy.

Bundled together, these steps — tight metabolic control, no smoking, and never missing an eye exam — turn a leading cause of blindness into a largely preventable one. The exam is the piece people skip because they "see fine." Remember that seeing fine is exactly when the disease is most treatable and most invisible.

11. Recent Research and Advances

The field is moving quickly, and most advances aim at finding the disease sooner and treating it less invasively. Artificial-intelligence screening is the headline development: deep-learning systems can now read retinal photographs and flag referable disease with accuracy comparable to specialists, and an autonomous system became the first FDA-authorized AI diagnostic in any field of medicine in 2018. This promises to bring screening into primary-care clinics, pharmacies, and underserved regions where eye specialists are scarce — directly attacking the "missed exam" problem at the heart of preventable blindness.

On the treatment side, longer-lasting anti-VEGF drugs and dosing strategies are reducing the burden of frequent injections, and newer agents targeting additional pathways (such as the angiopoietin–Tie2 system) aim to dry the retina more durably. Sustained-release implants and port-delivery systems are being developed so patients need fewer office visits. Researchers are also studying whether anti-VEGF injections can serve as a primary treatment for proliferative disease in place of laser, building on the Protocol S findings.

Wide-field imaging now captures far more of the retina in a single shot, revealing peripheral disease that older cameras missed, and OCT angiography maps retinal blood flow without dye injection. Together with home-monitoring tools and tighter integration of diabetes and eye care, the trajectory is clear: catch the disease earlier, treat it more conveniently, and lose fewer eyes to a condition we already know how to control.

12. References & Research

Historical Background

Doctors could not study the living retina until Hermann von Helmholtz invented the ophthalmoscope in 1851, which for the first time let physicians look directly into the back of the eye and see the changes diabetes causes. For more than a century afterward, diabetic retinopathy could be observed but not effectively treated. That changed in the 1970s and 1980s, when two landmark American trials — the Diabetic Retinopathy Study (DRS) and the Early Treatment Diabetic Retinopathy Study (ETDRS) — proved that laser photocoagulation could dramatically reduce blindness, establishing laser as the standard of care for a generation. The next revolution came in the 2000s with the discovery of VEGF's central role and the arrival of anti-VEGF injections, which transformed the treatment of macular edema and, increasingly, proliferative disease. Most recently, the rise of artificial-intelligence screening has begun to address the oldest problem of all: finding the silent disease in time.

Key Research Papers

Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. The Lancet. 2010;376(9735):124-136.
Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(3):412-418.
Yau JWY, Rogers SL, Kawasaki R, et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care. 2012;35(3):556-564.
Aiello LP, Gardner TW, King GL, et al. Diabetic Retinopathy. Diabetes Care. 1998;21(1):143-156.
The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine. 1993;329(14):977-986.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352(9131):837-853.
The ACCORD Study Group and ACCORD Eye Study Group. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. New England Journal of Medicine. 2010;363(3):233-244.
Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for Diabetic Macular Edema (ETDRS Report Number 1). Archives of Ophthalmology. 1985;103(12):1796-1806.
The Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema (Protocol T). New England Journal of Medicine. 2015;372(13):1193-1203.
Gross JG, Glassman AR, Jampol LM, et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy (Protocol S). JAMA. 2015;314(20):2137-2146.
Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for Diabetic Macular Edema (RISE and RIDE). Ophthalmology. 2012;119(4):789-801.
Gulshan V, Peng L, Coram M, et al. Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. JAMA. 2016;316(22):2402-2410.
Grzybowski A, Brona P, Lim G, et al. Artificial intelligence for diabetic retinopathy screening: a review. Eye. 2020;34(3):451-460.
Wong TY, Sabanayagam C. Strategies to Tackle the Global Burden of Diabetic Retinopathy: From Epidemiology to Artificial Intelligence. Ophthalmologica. 2020;243(1):9-20.

Research Papers

The links below run live PubMed searches so you can explore the latest peer-reviewed literature on diabetic retinopathy and its management. Each opens current results in a new tab.

Connections

Back to Table of Contents